> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves Adcetris for Large Cell Lymphoma
- URL: https://www.fdaweb.com/fda-approves-adcetris-for-large-cell-lymphoma/
- Published: 2017-11-09T12:00:00.000Z
- Updated: 2026-09-14T23:00:59.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5140101

FDA has approved a Seattle Genetics’ supplemental BLA for Adcetris (brentuximab vedotin) for treating adult patients with primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides who have received prior systemic therapy. Approval was based on data from the ALCANZA Phase 3 trial that showed an objective response rate at four months of 56% for brentuximab vedotin arm versus 12% in the physician’s choice arm, according to an [FDA release](https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm584543.htm?utm%5Fcampaign=Oncology%2011%2F9&utm%5Fmedium=email&utm%5Fsource=Eloqua&elqTrackId=06d11c937bec44c79cd3d453daecb608&elq=a0ce27d293964018948d65d75404fc9f&elqaid=1289&elqat=1&elqCampaignId=770). The complete response rate was also superior in the brentuximab vedotin arm versus the physician’s choice arm, 16% to 2%.